State of the science and future directions for research on HIV and cancer: Summary of a joint workshop sponsored by IARC and NCI

TY - JOUR

T1 - State of the science and future directions for research on HIV and cancer

T2 - Summary of a joint workshop sponsored by IARC and NCI

AU - Engels, Eric A

AU - Shiels, Meredith S

AU - Barnabas, Ruanne V

AU - Bohlius, Julia

AU - Brennan, Paul

AU - Castilho, Jessica

AU - Chanock, Stephen J

AU - Clarke, Megan A

AU - Coghill, Anna E

AU - Combes, Jean-Damien

AU - Dryden-Peterson, Scott

AU - D'Souza, Gypsyamber

AU - Gopal, Satish

AU - Jaquet, Antoine

AU - Lurain, Kathryn

AU - Makinson, Alain

AU - Martin, Jeffrey

AU - Muchengeti, Mazvita

AU - Newton, Robert

AU - Okuku, Fred

AU - Orem, Jackson

AU - Palefsky, Joel M

AU - Ramaswami, Ramya

AU - Robbins, Hilary A

AU - Sigel, Keith

AU - Silver, Sylvia

AU - Suneja, Gita

AU - Yarchoan, Robert

AU - Clifford, Gary M

N1 - © 2023 International Agency for Research on Cancer; licensed by UICC and The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.

PY - 2023/9/15

Y1 - 2023/9/15

N2 - An estimated 38 million people live with human immunodeficiency virus (HIV) worldwide and are at excess risk for multiple cancer types. Elevated cancer risks in people living with HIV (PLWH) are driven primarily by increased exposure to carcinogens, most notably oncogenic viruses acquired through shared transmission routes, plus acceleration of viral carcinogenesis by HIV-related immunosuppression. In the era of widespread antiretroviral therapy (ART), life expectancy of PLWH has increased, with cancer now a leading cause of co-morbidity and death. Furthermore, the types of cancers occurring among PLWH are shifting over time and vary in their relative burden in different parts of the world. In this context, the International Agency for Research on Cancer (IARC) and the US National Cancer Institute (NCI) convened a meeting in September 2022 of multinational and multidisciplinary experts to focus on cancer in PLWH. This report summarizes the proceedings, including a review of the state of the science of cancer descriptive epidemiology, etiology, molecular tumor characterization, primary and secondary prevention, treatment disparities and survival in PLWH around the world. A consensus of key research priorities and recommendations in these domains is also presented.

AB - An estimated 38 million people live with human immunodeficiency virus (HIV) worldwide and are at excess risk for multiple cancer types. Elevated cancer risks in people living with HIV (PLWH) are driven primarily by increased exposure to carcinogens, most notably oncogenic viruses acquired through shared transmission routes, plus acceleration of viral carcinogenesis by HIV-related immunosuppression. In the era of widespread antiretroviral therapy (ART), life expectancy of PLWH has increased, with cancer now a leading cause of co-morbidity and death. Furthermore, the types of cancers occurring among PLWH are shifting over time and vary in their relative burden in different parts of the world. In this context, the International Agency for Research on Cancer (IARC) and the US National Cancer Institute (NCI) convened a meeting in September 2022 of multinational and multidisciplinary experts to focus on cancer in PLWH. This report summarizes the proceedings, including a review of the state of the science of cancer descriptive epidemiology, etiology, molecular tumor characterization, primary and secondary prevention, treatment disparities and survival in PLWH around the world. A consensus of key research priorities and recommendations in these domains is also presented.

U2 - 10.1002/ijc.34727

DO - 10.1002/ijc.34727

M3 - Review article

C2 - 37715370

SN - 0020-7136

JO - International Journal of Cancer

JF - International Journal of Cancer

ER -